An oriented phase II trial of THP-adriamycin in breast carcinoma

THP-ADM is a new anthracycline with broad antitumor activity without cardiac toxicity or alopecia in experimental models. Phase I studies had established a proposed dose for phase II trials of 50 mg/m2 every three weeks. This modality gave an insignificant result in breast carcinoma. Cellular pharma...

Full description

Saved in:
Bibliographic Details
Published inBiomedicine & pharmacotherapy Vol. 40; no. 10; p. 376
Main Authors Mathé, G, Umezawa, H, Oka, S, Misset, J L, Brienza, S, de Vassal, F, Musset, M, Ribaud, P, Tapiero, H
Format Journal Article
LanguageEnglish
Published France 1986
Subjects
Adult
Aged
Blood Cell Count
Breast Neoplasms - drug therapy
Doxorubicin - adverse effects
Doxorubicin - analogs & derivatives
Doxorubicin - therapeutic use
Drug Evaluation
Female
Heart Diseases - chemically induced
Humans
Middle Aged
Neoplasm Metastasis
Online AccessGet more information

Cover

More Information
Summary:THP-ADM is a new anthracycline with broad antitumor activity without cardiac toxicity or alopecia in experimental models. Phase I studies had established a proposed dose for phase II trials of 50 mg/m2 every three weeks. This modality gave an insignificant result in breast carcinoma. Cellular pharmacokinetics suggested that a longer time of administration could be more efficient. In this phase II trial oriented to advanced breast cancer, we have used 3 consecutive daily doses of 20 mg/m2/day in monthly cycles with dose escalation in each patient. We have observed 28% partial remissions (PR). Two patients previously treated with adriamycin had PR. Significantly less alopecia and no cardiac toxicity were observed.
ISSN:0753-3322